Teva 1Q Revenues: $5.1 billion (+25%) 1Q Earnings: $855.0 million (+12%) Comments: Revenues in the U.S. were +46% to $2.8 billion, primarily due to the inclusion of Cephalon product sales. Revenues in Europe were $1.3 billion (-2%), impacted by ongoing macro-economic conditions and healthcare reforms in key European markets. Rest of the World sales totaled +21% to $1 billion, driven by the inclusion of Taiyo and Cephalon. Generic revenues were $2.6 billion (including API revenues of $199 mill...